A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Instillation of TARA-002 in Adults with High-Grade Non-Muscle Invasive Bladder Cancer

Go Back to All Clinical Trials

A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Instillation of TARA-002 in Adults with High-Grade Non-Muscle Invasive Bladder Cancer

Brief description of study

Study TARA-002-101-Ph2 is an open-label Phase 2 study to investigate the safety and efficacy of TARA-002 administered intravesically in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1).

Clinical Study Identifier: s25-01411

ClinicalTrials.gov Identifier: NCT05951179

Principal Investigator: Katie S. Murray.

Other Investigators: Victor Ricardo Adorno Febles, James S Wysock, Wei Phin Tan, Minas Platon Economides, Laura Catherine Bauer, William C Huang, David R. Wise.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies